A retrospective study compared clinical outcomes of standard-dose osimertinib to first-generation TKIs in untreated EGFR-positive NSCLC with LM, showing superior mPFS (16.9 months vs. 8.6 months) and mOS (26.6 months vs. 20.0 months) in the osimertinib group (18). This evidence concerns the gene EGFR and non-small cell lung carcinoma.